trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Genetically modified viruses can be used to cure genetic diseases

the verdict
SUPPORTED
the evidence backs this
Recorded sources
5 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that genetically modified viruses can be used to cure genetic diseases?

Yes. Genetically modified viral vectors, such as adeno-associated viruses (AAVs), are successfully used in preclinical and clinical settings to deliver therapeutic genetic material and gene-editing tools to treat and correct genetic diseases.

Verdict: SUPPORTED · 5 sources for, 0 against · Last checked

The analysis

The retrieved papers consistently demonstrate that viral vectors (such as AAVs) can be used to deliver gene therapies and gene-editing technologies to correct genetic mutations, restore biochemical homeostasis, and improve phenotypes in animal models and clinical applications of genetic diseases. There is no contradictory evidence in the retrieved literature.

Evidence for · 5
Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases
2021
Demonstrates that adeno-associated virus vectors can deliver gene-editing tools to correct pathogenic mutations and ameliorate disease phenotypes in animal models of genetic diseases.
Get citation
Jang, H., Jo, D., Cho, C. S., Shin, J., Seo, J., Yu, G., Gopalappa, R., Kim, D., Cho, S., Kim, J. H., & Kim, H. (2021). Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases. doi.org. https://doi.org/10.1038/s41551-021-00788-9

See more details
More for · 4
Efficacy of adeno-associated virus gene therapy in a MNGIE murine model enhanced by chronic exposure to nucleosides
2020
Shows that AAV-mediated gene therapy restores biochemical homeostasis and improves functional phenotypes in a murine model of a genetic disorder.
Get citation
Vila-Julià, F., Cabrera-Pérez, R., Cámara, Y., Molina-Berenguer, M., Lope-Piedrafita, S., Hirano, M., Mingozzi, F., Torres-Torronteras, J., & Martí, R. (2020). Efficacy of adeno-associated virus gene therapy in a MNGIE murine model enhanced by chronic exposure to nucleosides. doi.org. https://doi.org/10.1016/j.ebiom.2020.103133

Viral vector-based gene therapies in the clinic: An update.
2026
Reviews FDA-approved viral vector-based gene therapies targeting various genetic and monogenic disorders, illustrating clinical translation.
Get citation
KS, P., YI, C., S, M., & Z, Z. (2026). Viral vector-based gene therapies in the clinic: An update.. doi.org. https://doi.org/10.1002/btm2.70106

Gene Therapy Using Recombinant Adeno-Associated Virus for Leber Congenital Amaurosis Induced by RPE65 Mutation.
2026
Discusses the use of recombinant adeno-associated virus vectors to deliver functional genes to treat genetic retinal dystrophies like Leber congenital amaurosis.
Get citation
I, O., A, T., M, S., & A, S. (2026). Gene Therapy Using Recombinant Adeno-Associated Virus for Leber Congenital Amaurosis Induced by RPE65 Mutation.. doi.org. https://doi.org/10.2147/opth.s593854

Prime editing of a pathogenic <i>Scn1a</i> allele ameliorates seizure phenotypes in a GEFS<sup>+</sup> mouse model.
2026
Demonstrates that AAV delivery of prime editing components corrects genetic mutation and ameliorates seizure phenotypes in a mouse model of an inherited epileptic disorder.
Get citation
L, K., F, P., M, R., D, B., N, M., PI, K., E, I., L, S., A, T., E, V., H, W., X, Z., K, K., HU, Z., & G, S. (2026). Prime editing of a pathogenic <i>Scn1a</i> allele ameliorates seizure phenotypes in a GEFS<sup>+</sup> mouse model.. doi.org. https://doi.org/10.1126/scitranslmed.adz2557

Related receipts

What does the evidence say?

The retrieved papers consistently demonstrate that viral vectors (such as AAVs) can be used to deliver gene therapies and gene-editing technologies to correct genetic mutations, restore biochemical homeostasis, and improve phenotypes in animal models and clinical applications of genetic diseases. There is no contradictory evidence in the retrieved literature.

Receipt History
first checked06 Aug 2026
judged → SUPPORTED · 8906 Aug 2026
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work